One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema.

BACKGROUND AND

OBJECTIVE

This study assessed real-world treatment patterns and 1-year outcomes among patients with diabetic macular edema (DME) initiating faricimab.

PATIENTS AND

METHODS

FARETINA-DME is a retrospective study using data from the IRIS® Registry for patients diagnosed with DME initiating faricimab from February 2022 to March 2023.

RESULTS

Seven hundred eighty-six (786) treatment-naive patients (970 eyes) and 4,862 patients (6,728 eyes) previously treated with anti-VEGF therapy were included. Visual acuity improved by 4.5 ± 15.8 (mean ± SD) letters in treatment-naive eyes (P < 0.001) and was maintained in previously treated eyes at injection-7. Central subfield thickness (CST) improved by -48.7 ± 82.7 μm in treatment-naive and -50.7 ± 101.1 μm in previously treated eyes (both P < 0.0001); 42.3% and 43.8% had achieved/maintained CST ≤ 280 μm at injection-7. Dosing frequency was reduced during the second 6 months (mean 1.9 to 2.7 injections) versus the first 6 months (3.4 to 3.9) of treatment.

CONCLUSION

One-year outcomes among patients with DME initiating faricimab in clinical practice support the real-world effectiveness and extended durability of treatment.